Navigation Links
GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
Date:8/11/2008

ATLANTA, Aug. 11 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based, biopharmaceutical firm (the Company), developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its financial results and provided an operational update for the six months ended June 30, 2008.

Financial Results for the Three Months and Six Months Ended June 30, 2008

The Company recorded a net loss of $1,284,352 for the three months ended June 30, 2008, compared to $1,333,126 for the same period in 2007. For the six months ended June 30, 2008, the Company's net loss was $1,966,862 as compared to $1,920,407 in 2007. Net losses for 2008 were partially offset by grant revenues of $376,078 and $976,069 for the three month and six month periods, respectively, related to the Company's grant from the National Institutes of Health in support of its HIV/AIDS vaccine development activities. As of June 30, 2008, the Company reported cash balances totaling $3,133,839.

Summarized financial information is attached. Further information concerning the Company's financial position and results of operations are included in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission.

Management Commentary

Robert McNally, GeoVax's President & CEO, commented, "We are pleased with our six month financial results, including our operational expenses and cash position. Our operational expenses are minimal for a company of our size and stage of clinical trial development. We are particularly pleased with the financing strategy provided by the $10 million common stock purchase agreement with Fusion Capital Fund II, LLC. Funding from the Fusion facility will be utilized for the large Phase 2 preventative AIDS vaccine clinical trial planned to begin this fall and initiation of the therapeutic trial in HIV infected and drug-treated humans."

Dr. McN
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. GeoVax Further Strengthens Management Team
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
4. Genaera Corporation Announces Second Quarter Financial Results
5. China Biologic Products Announces Second Quarter 2008 Results Conference Call
6. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
7. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
8. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
9. ThirdBiotech Announces Kemeta as Newest Sponsor
10. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
11. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... used for detailed studies of what happens on the ... research, among other applications. A group of researchers from ... cell membranes form across a large number of vertical ... the interior of a cell and its surroundings takes ... surface layer that holds the cell together and that ...
(Date:9/2/2014)... 2, 2014  TransCelerate BioPharma Inc. ("TransCelerate") today ... for protecting personal data in Clinical Study Reports ... others. The document describes an approach to apply ... and other related clinical trial documents, and is ... of the TransCelerate CSR Redaction approach is to ...
(Date:9/2/2014)... 2014 Orexigen Therapeutics, Inc. (Nasdaq: ... Trademark Office (PTO) has issued a patent related to ... loss. NB32 is a fixed-dose combination of naltrexone sustained ... No. 8,815,889 claims methods for treating insulin resistance using ... in 2024. If NB32 is approved for use in ...
(Date:9/2/2014)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... three large odour control systems for waste water treatment plants ... are consistent with the market resurgence in North ... CEO. "After a difficult period of restraint in our core ... sales growth. Our lower cost structure, technology improvements and supply ...
Breaking Biology Technology:Nano-forests to reveal secrets of cells 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4
... 13 /PRNewswire-Asia/ -- IVT Corporation announced today that,it will demonstrate ... Hong Kong on Nov. 18-19, at Booth F08, and CES ... reducing risk of diseases and,assisting with emergency rescue. , ... It includes: , 1) ...
... Nov. 12 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:,SSRX) ("3SBio" or ... developing, manufacturing and marketing,biopharmaceutical products, today announced its unaudited ... , , Third Quarter 2009 Financial ... by 35.8% over the third quarter of 2008 to, ...
... AvidBiotics Corp. announced the issuance of foundational ... massive diversity within precisely targeted sites of protein-encoding ... to as Diversity Generating Retroelements (DGR) and patents ... and in Europe (#1,173,995). UCLA and AvidBiotics ...
Cached Biology Technology:IVT will Demo Mobile Health System at GSMA Mobile Asia Congress and CES 2010 23SBio Inc. Announces Unaudited Third Quarter 2009 Results 23SBio Inc. Announces Unaudited Third Quarter 2009 Results 33SBio Inc. Announces Unaudited Third Quarter 2009 Results 43SBio Inc. Announces Unaudited Third Quarter 2009 Results 53SBio Inc. Announces Unaudited Third Quarter 2009 Results 63SBio Inc. Announces Unaudited Third Quarter 2009 Results 73SBio Inc. Announces Unaudited Third Quarter 2009 Results 83SBio Inc. Announces Unaudited Third Quarter 2009 Results 93SBio Inc. Announces Unaudited Third Quarter 2009 Results 103SBio Inc. Announces Unaudited Third Quarter 2009 Results 113SBio Inc. Announces Unaudited Third Quarter 2009 Results 123SBio Inc. Announces Unaudited Third Quarter 2009 Results 133SBio Inc. Announces Unaudited Third Quarter 2009 Results 143SBio Inc. Announces Unaudited Third Quarter 2009 Results 153SBio Inc. Announces Unaudited Third Quarter 2009 Results 163SBio Inc. Announces Unaudited Third Quarter 2009 Results 173SBio Inc. Announces Unaudited Third Quarter 2009 Results 183SBio Inc. Announces Unaudited Third Quarter 2009 Results 193SBio Inc. Announces Unaudited Third Quarter 2009 Results 203SBio Inc. Announces Unaudited Third Quarter 2009 Results 21AvidBiotics Corp. Granted Key U.S. and European Patents on Unique Protein Modification Platform 2
(Date:9/2/2014)... history of scientific research on mountain ecosystems, looks ... and sets an agenda for biodiversity conservation throughout ... gloom and mountain glory revisited: A survey of ... appears online in the Journal of Mountain ... Tufts University, Jodi A. Hilty of the Wildlife ...
(Date:9/2/2014)... always true that digital distribution of media will ... means, at least when file sizes are large. ... in Yale,s Journal of Industrial Ecology ... for consoles such as PlayStation3. Researchers found that ... greenhouse gas emissions than game files downloaded over ...
(Date:9/2/2014)... R.I. [Brown University] It,s hard to comprehend how ... world has become without knowing what it was before ... pre-human rate was 10 times lower than scientists had ... times worse. , Extinctions are about 1,000 times more ... people came along. The explanation from lead author Jurriaan ...
Breaking Biology News(10 mins):An uphill climb for mountain species? 2An uphill climb for mountain species? 3Extinctions during human era worse than thought 2Extinctions during human era worse than thought 3
... A University of Utah biologist and an international research team ... hope for new ways to attack the major pest, which ... The voracious mites, which technically are not insects, can ... The mites, newly revealed and sequenced genome contains a variety ...
... of Illinois at Chicago College of Medicine describe for ... checkpoint enzymes that must be chemically modified to enable ... thought to play a key role in cancer and ... Nature Structural and Molecular Biology . Telomeres are ...
... recent opening of its new Biomolecular Labeling Laboratory, the ... one of a small handful of facilities in the ... isotopes to make them easier to analyze. The new ... in biomedical fields who also want to take advantage ...
Cached Biology News:Big pest, small genome 2Big pest, small genome 3Big pest, small genome 4UIC study identifies a key molecular switch for telomere extension by telomerase 2Tags? We're it. NIST opens new 'biolabeling' research facility 2
... is a very sensitive immunohistochemical tool for ... both anti-von Willebrand Factor and anti-CD31 primary ... of species. This AP kit provides a ... frozen and paraffin-embedded sections in human (both ...
... Applied Biosystems and MDS Sciex ... System, a high performance hybrid triple ... the drug discovery, drug development or ... (LIT) Technology from the leaders in ...
... 18 amino acid synthetic peptide whose sequence corresponds to residues 1-18 ... (amino to carboxy terminus): M(1) - A - S - A ... S - P - R - D - A - A ... be used for neutralization and control experiments with the polyclonal antibody ...
... is a fixative useful for routine procedures. ... is stable and will decalcify small bone ... can be stained successfully with most stains, ... stabilizes red blood cell membranes and cosinophil ...
Biology Products: